NASDAQ:SBFM Sunshine Biopharma 8/12/2025 Earnings Report $1.09 -0.01 (-0.91%) As of 02:52 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sunshine Biopharma EPS ResultsActual EPS-$0.39Consensus EPS -$0.11Beat/MissMissed by -$0.28One Year Ago EPSN/ASunshine Biopharma Revenue ResultsActual Revenue$9.41 millionExpected Revenue$12.10 millionBeat/MissMissed by -$2.69 millionYoY Revenue GrowthN/ASunshine Biopharma Announcement DetailsQuarterDate8/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Sunshine Biopharma Earnings HeadlinesSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 5 at 1:00 AM | Profits Run (Ad)Sunshine Biopharma stock rises after Health Canada approval for DomperidoneOctober 28, 2025 | za.investing.comSunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | finanznachrichten.deSunshine Biopharma Inc.: Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineOctober 21, 2025 | finanznachrichten.deSee More Sunshine Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email. Email Address About Sunshine BiopharmaSunshine Biopharma (NASDAQ:SBFM) is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors. Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines. The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.View Sunshine Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should Knowonsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-EarningsA Prada Payday: Is AMC Back in Style? Upcoming Earnings ARM (5/6/2026)AppLovin (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
